Rituximab in Refractory Myasthenia Gravis
Loading...
Date
2020-02-17
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
faculty of Basic Medical Science - Libyan International Medical University
Abstract
Myasthenia gravis (MG) is an autoimmune disease caused by complement-fixing
antibodies against acetylcholine receptors (AChR). Cholinesterase inhibitors,
Glucocorticoid , which is currently recommended as a first-line treatment for MG,
although it has drawbacks, including possible toxicity and inefficiency in patients
with refractory MG and traditional immunosuppressants stay the standard treatments
at present, but they have demonstrated limitations and often unsatisfactory efficacy so
the target specific therapeutic interventions should therefore be directed against
antibodies For example, Rituximab is a monoclonal antibody (mAbs) that could be
more active and longer lasting with less serious side effects.
Description
Myasthenia gravis (MG) from Greek: myos = muscle, asthenos = weakness, and
Latin: gravis = severe, is an autoimmune neuromuscular disease primarily mediated
by antibodies (Abs) targeting either the nicotinic acetylcholine receptor (AChR), or
the components of the postsynaptic membrane at the neuromuscular junction (NMJ)
leading to impaired neuromuscular transmission.
(1)
Standard treatment such as Cholinesterase inhibitors cannot completely relieve the
symptoms of MG or prevent the progression of the disease, glucocorticoids are also
widely used to treat MG often causing severe adverse effects, and immunosuppressant
such as glucocorticosteroids , often used as first-line MG therapies but for long-term
use of immunosuppressive agents, often leads to significant side effects
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwised noted, this item's license is described as Attribution 3.0 United States